Literature DB >> 9579564

Retention of the CDKN2A locus and low frequency of point mutations in primary and metastatic cutaneous malignant melanoma.

A Ruiz1, S Puig, M Lynch, T Castel, X Estivill.   

Abstract

CDKN2A has been found mutated in melanoma families which show linkage to chromosome 9p21. In contrast, a low mutation rate has been found in melanomas, suggesting that CDKN2A might not be the first target for mutation in the development of this type of tumour. To elucidate the role of the CDKN2A gene and its alternative transcript p19ARF in the development of cutaneous malignant melanoma (CMM) we have analyzed 48 primary and metastasic CMM tumours for mutations and for loss of heterozygosity (LOH). Only one point mutation was detected (2%), while hemizygous deletions were identified in 20% of these tumours. Retention of the CDKN2A locus was found in 10 (47%) tumours with deletions at one or both sides of CDKN2A, suggesting that loss of this gene is not involved in CMM-tumour initiation and that another tumour-suppressor gene involved in melanoma is located at 9p21.

Entities:  

Mesh:

Year:  1998        PMID: 9579564     DOI: 10.1002/(sici)1097-0215(19980504)76:3<312::aid-ijc4>3.0.co;2-y

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15.

Authors:  José Luis Soto Martínez; Carmen M Cabrera Morales; Sabio Serrano Ortega; Miguel Angel López-Nevot
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

2.  LOH analysis of free DNA in the plasma of patients with mucosal malignant melanoma in the head and neck.

Authors:  Ryo Takagi; Daisuke Nakamoto; Jun-etsu Mizoe; Hirohiko Tsujii
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

3.  Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma.

Authors:  Joan A Puig-Butillé; Celia Badenas; Zighereda Ogbah; Cristina Carrera; Paula Aguilera; Josep Malvehy; Susana Puig
Journal:  Exp Dermatol       Date:  2013-02       Impact factor: 3.960

4.  Rapid repair of UVA-induced oxidized purines and persistence of UVB-induced dipyrimidine lesions determine the mutagenicity of sunlight in mouse cells.

Authors:  Ahmad Besaratinia; Sang-In Kim; Gerd P Pfeifer
Journal:  FASEB J       Date:  2008-03-07       Impact factor: 5.191

5.  Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma.

Authors:  Caroline Conway; Samantha Beswick; Faye Elliott; Yu-Mei Chang; Juliette Randerson-Moor; Mark Harland; Paul Affleck; Jerry Marsden; D Scott Sanders; Andy Boon; Margaret A Knowles; D Timothy Bishop; Julia A Newton-Bishop
Journal:  Genes Chromosomes Cancer       Date:  2010-05       Impact factor: 5.006

6.  Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B.

Authors:  José Luis Soto; Carmen M Cabrera; Salvio Serrano; Miguel Angel López-Nevot
Journal:  BMC Cancer       Date:  2005-04-08       Impact factor: 4.430

7.  Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group.

Authors:  G Palmieri; A Cossu; P A Ascierto; G Botti; M Strazzullo; A Lissia; M Colombino; M Casula; C Floris; F Tanda; M Pirastu; G Castello
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

8.  The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.

Authors:  F Lesueur; M de Lichy; M Barrois; G Durand; J Bombled; M-F Avril; A Chompret; F Boitier; G M Lenoir; B Bressac-de Paillerets; Monique Baccard; Bertrand Bachollet; Pascaline Berthet; Valérie Bonadona; Jean-Marie Bonnetblanc; Olivier Caron; Jacqueline Chevrant-Breton; Jean-François Cuny; Stéphane Dalle; Michèle Delaunay; Liliane Demange; Julie De Quatrebarbes; Jean-François Doré; Marc Frénay; Jean-Pierre Fricker; Marion Gauthier-Villars; Paul Gesta; Sophie Giraud; Philippe Gorry; Florent Grange; Andrew Green; Laetitia Huiart; Nicolas Janin; Pascal Joly; Delphine Kérob; Christine Lasset; Dominique Leroux; Jean-Marc Limacher; Michel Longy; Sandrine Mansard; Karine Marrou; Tanguy Martin-Denavit; Christine Mateus; Eve Maubec; Laurence Olivier-Faivre; Vincent Orlandini; Pascal Pujol; Bruno Sassolas; Dominique Stoppa-Lyonnet; Luc Thomas; Pierre Vabres; Laurence Venat; Ewa Wierzbicka; Hélène Zattara
Journal:  Br J Cancer       Date:  2008-07-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.